Search research articles
Contact Us
Filters
Showing results (51-60 of 56) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 56 results.
ESMO Real World Data and Digital Oncology
|
April 20, 2026
Optimisation and validation of line-of-therapy advancement algorithms in advanced/metastatic non-small-cell lung cancer: an I-O Optimise study
S Lay-Flurrie, A Greystoke, C Rault, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 5, 2025
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic NSCLC Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1
Solange Peters, Meredith M Regan, Luis G Paz-Ares, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 13, 2024
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial
Martin Reck, Tudor-Eliade Ciuleanu, Michael Schenker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 12, 2022
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227
Julie R Brahmer, Jong-Seok Lee, Tudor-Eliade Ciuleanu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2026
Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer
Hossein Borghaei, David Balli, Luis G Paz-Ares, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 5, 2023
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1
Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 56) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 56 results.
ESMO Real World Data and Digital Oncology
|
April 20, 2026
Optimisation and validation of line-of-therapy advancement algorithms in advanced/metastatic non-small-cell lung cancer: an I-O Optimise study
S Lay-Flurrie, A Greystoke, C Rault, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 5, 2025
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic NSCLC Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1
Solange Peters, Meredith M Regan, Luis G Paz-Ares, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 13, 2024
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial
Martin Reck, Tudor-Eliade Ciuleanu, Michael Schenker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 12, 2022
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227
Julie R Brahmer, Jong-Seok Lee, Tudor-Eliade Ciuleanu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2026
Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer
Hossein Borghaei, David Balli, Luis G Paz-Ares, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 5, 2023
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1
Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, et al.
Page
of 6